Fosamax and Osteonecrosis of the Jaw: Understanding the Link and Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Science to Specific Medication Risks

The legacy of general health and science information has long provided a foundational context for understanding broad wellness principles, from nutritional guidelines to disease prevention strategies. Within this framework, discussions often pivot from abstract health concepts to more specific, actionable concerns. One such pivot involves the transition from general awareness of medication side effects to focused examination of risks associated with specific pharmaceuticals. For instance, while the general health context may address the risks associated with pharmaceutical use, the occupational exposure concern narrows this lens to environments where workers might encounter substances like bisphosphonates. In mass production settings, the handling of such compounds during manufacturing processes introduces distinct exposure pathways. This shift requires moving beyond population-level health advisories to consider workplace-specific variables, such as duration of contact, concentration levels, and protective measures. The bridge concept thus reframes the discussion from a broad health science perspective to a targeted hazard assessment, emphasizing the need for tailored risk management protocols in industrial contexts.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the legacy of general health science, we now focus on a specific medication: Fosamax (alendronate), a bisphosphonate used for osteoporosis and Paget's disease. While bisphosphonates are effective in reducing fractures, they have been associated with a rare but serious adverse effect: osteonecrosis of the jaw (ONJ). This condition involves necrotic bone in the jaw, often triggered by dental procedures or infection. Understanding the causation and risk factors is crucial for patients and healthcare providers. The following sections delve into the evidence linking Fosamax to ONJ, drawing on clinical studies and prescribing information.

Fosamax: Mechanism and Approved Uses

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition involving necrotic bone in the jaw that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves exposed bone in the maxillofacial region that does not heal within eight weeks after identification. Diagnosis is based on clinical examination and imaging, often ruling out metastatic disease or other jaw pathologies. The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Risk Factors

Mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover. In the jaw, which has high remodeling rates due to dental function and infection, this suppression may impair healing after dental procedures or microtrauma, leading to necrotic bone exposure. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone, and can accumulate in bone tissue over years of use, potentially increasing toxicity. Risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Evidence from Studies: Risk Over Time

A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702). The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Causation Considerations

Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under Section 5.4 "Osteonecrosis of the Jaw" that describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of use has not been determined and suggests considering drug discontinuation after 3 to 5 years for low-risk patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the label does not provide specific guidance on routine dental monitoring or pre-treatment dental evaluation, which may be considered a gap in risk communication. Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax use and ONJ onset, excluding other causes such as cancer or radiation therapy, and documenting the absence of other risk factors. The evidence shows that ONJ risk increases with longer exposure and that risk diminishes after discontinuation, supporting a causal link (https://pubmed.ncbi.nlm.nih.gov/39400702). However, the condition is rare, and many cases occur in the presence of additional risk factors like dental procedures or comorbidities. For patients who develop ONJ, management includes discontinuation of the bisphosphonate, conservative debridement, infection control, and avoidance of further dental surgery. The label advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of dental procedures or other risk factors. The prescribing information includes warnings about this risk, but the absolute risk remains low. Patients and clinicians should weigh the benefits of fracture reduction against the rare but serious risk of ONJ, and consider dental evaluation before initiating therapy and during prolonged use.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that can increase the risk of osteonecrosis of the jaw (ONJ), a condition where jawbone tissue dies and becomes exposed. The risk is higher with longer use and in patients undergoing dental procedures. Studies show a threefold increased risk after 2-3 years and eightfold after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and comorbidities like periodontal disease, anemia, or infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Duration of bisphosphonate use also increases risk.

How common is ONJ in Fosamax users?

ONJ is rare. A cohort study found absolute risk approximately 0.05% after 5 years of treatment (https://pubmed.ncbi.nlm.nih.gov/39400702). The risk increases with longer exposure but remains low overall.

What should I do if I need dental work while taking Fosamax?

Consult your healthcare provider. The prescribing information suggests that discontinuing bisphosphonate treatment may reduce ONJ risk for patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A dental evaluation before starting therapy and during prolonged use is recommended.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.